Top

Published in:

01-04-2009

Ebselen Improves Ischemia-Reperfusion Injury After Rat Lung Transplantation

Authors: Jürg Hamacher, Uz Stammberger, Elvira Weber, Rudolf Lucas, Albrecht Wendel

Published in: Lung | Issue 2/2009

Abstract

The heterocyclic organic compound ebselen (2-phenyl-1,2-benizsoselenazol-3(2H)-one) is a glutathione peroxidase mimick with protective properties against oxidative injury. Ebselen also has anti-inflammatory activity, including attenuation of tumor necrosis factor release and increase of interleukin-10, as shown in vivo, in inflammatory and ischemia-reperfusion injuries, including those of the lung. This study was designed to assess its effect on severe ischemia-reperfusion injury in a model of left-sided rat lung isotransplantation. Orthotopic single left-sided lung allotransplantation (Wistar to Wistar) was performed in female rats after a total ischemic time of 18 h. In nine recipients given 500 mg/kg oral ebselen 1 h before transplantation, graft PaO₂/FiO₂ was improved 24 h after transplantation, as evidenced with a mean (standard deviation) PaO₂ of 139 (61) mmHg vs. eight controls with 65 (33) mmHg (p = 0.009). Bronchoalveolar PMN count was reduced to approximately 50% in the ebselen group compared with controls, whereas no difference in the tumor necrosis factor content was found. We conclude that the improvement of lung function in ebselen-treated transplanted rats is mainly the result of the anti-inflammatory activity of the drug during reperfusion.

Parnham MJ, Kindt S (1984) A novel biologically active seleno-organic compound-III. Effects of PZ 51 (Ebselen) on glutathione peroxidase and secretory activities of mouse macrophages. Biochem Pharmacol 33:3247–3250. doi:10.1016/0006-2952(84)90085-6 PubMedCrossRef

Wendel A, Fausel M, Safayhi H, Tiegs G, Otter R (1984) A novel biologically active seleno-organic compound-II. Activity of PZ 51 in relation to glutathione peroxidase. Biochem Pharmacol 33:3241–3245. doi:10.1016/0006-2952(84)90084-4 PubMedCrossRef

Hattori R, Inoue R, Sase K, Eizawa H, Kosuga K, Aoyama T, Masayasu H, Kawai C, Sasayama S, Yui Y (1994) Preferential inhibition of inducible nitric oxide synthase by ebselen. Eur J Pharmacol 267:R1–R2PubMed

Wendel A, Otter R, Tiegs G (1986) Inhibition by ebselen of microsomal NADPH-cytochrome P450-reductase in vitro but not in vivo. Biochem Pharmacol 35:2995–2997. doi:10.1016/0006-2952(86)90376-X PubMedCrossRef

Cotgreave IA, Duddy SK, Kass GE, Thompson D, Moldeus P (1989) Studies on the anti-inflammatory activity of ebselen. Ebselen interferes with granulocyte oxidative burst by dual inhibition of NADPH oxidase and protein kinase C? Biochem Pharmacol 38:649–656. doi:10.1016/0006-2952(89)90211-6 PubMedCrossRef

Patrick RA, Peters PA, Issekutz AC (1993) Ebselen is a specific inhibitor of LTB4-mediated migration of human neutrophils. Agents Actions 40:186–190. doi:10.1007/BF01984060 PubMedCrossRef

Wendel A, Tiegs G (1986) A novel biologically active seleno-organic compound-VI. Protection by ebselen (PZ 51) against galactosamine/endotoxin-induced hepatitis in mice. Biochem Pharmacol 35:2115–2118. doi:10.1016/0006-2952(86)90578-2 PubMedCrossRef

Wendel A, Kuesters S, Tiegs G (1997) Ebselen: an in vivo immune response modifier. Biomed Environ Sci 10:253–259PubMed

Tiegs G, Kusters S, Kunstle G, Hentze H, Kiemer AK, Wendel A (1998) Ebselen protects mice against T cell-dependent, TNF-mediated apoptotic liver injury. J Pharmacol Exp Ther 287:1098–1104PubMed

10.

d’Alessio P, Moutet M, Coudrier E, Darquenne S, Chaudiere J (1998) ICAM-1 and VCAM-1 expression induced by TNF-alpha are inhibited by a glutathione peroxidase mimic. Free Radic Biol Med 24:979–987. doi:10.1016/S0891-5849(97)00396-1 PubMedCrossRef

11.

Briviba K, Roussyn I, Sharov VS, Sies H (1996) Attenuation of oxidation and nitration reactions of peroxynitrite by selenomethionine, selenocystine and ebselen. Biochem J 319(Pt 1):13–15PubMed

12.

Daiber A, Zou MH, Bachschmid M, Ullrich V (2000) Ebselen as a peroxynitrite scavenger in vitro and ex vivo. Biochem Pharmacol 59:153–160. doi:10.1016/S0006-2952(99)00309-3 PubMedCrossRef

13.

Ishii Y, Hashimoto K, Hirano K, Morishima Y, Mochizuki M, Masuyama K, Nomura A, Sakamoto T, Uchida Y, Sagai M, Sekizawa K (2000) Ebselen decreases ozone-induced pulmonary inflammation in rats. Lung 178:225–234PubMed

14.

Brodsky SV, Gealekman O, Chen J, Zhang F, Togashi N, Crabtree M, Gross SS, Nasjletti A, Goligorsky MS (2004) Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by Ebselen. Circ Res 94:377–384. doi:10.1161/01.RES.0000111802.09964.EF PubMedCrossRef

15.

Gao JX, Issekutz AC (1994) The effect of ebselen on T-lymphocyte migration to arthritic joints and dermal inflammatory reactions in the rat. Int J Immunopharmacol 16:279–287. doi:10.1016/0192-0561(94)90002-7 PubMedCrossRef

16.

Haraoka M, Matsumoto T, Mizunoe Y, Takahashi K, Kubo S, Koikawa Y, Tanaka M, Sakamoto Y, Sakumoto M, Nagafuji T (1995) Effect of ebselen on renal scarring in rats following renal infection. Chemotherapy 41:208–213PubMedCrossRef

17.

Johshita H, Sasaki T, Matsui T, Hanamura T, Masayasu H, Asano T, Takakura K (1990) Effects of ebselen (PZ51) on ischaemic brain oedema after focal ischaemia in cats. Acta Neurochir Suppl (Wien) 51:239–241

18.

Kondoh S, Nagasawa S, Kawanishi M, Yamaguchi K, Kajimoto S, Ohta T (1999) Effects of ebselen on cerebral ischemia and reperfusion evaluated by microdialysis. Neurol Res 21:682–686PubMed

19.

Sui H, Wang W, Wang PH, Liu LS (2005) Protective effect of antioxidant ebselen (PZ51) on the cerebral cortex of stroke-prone spontaneously hypertensive rats. Hypertens Res 28:249–254. doi:10.1291/hypres.28.249 PubMedCrossRef

20.

Kalayci M, Coskun O, Cagavi F, Kanter M, Armutcu F, Gul S, Acikgoz B (2005) Neuroprotective effects of ebselen on experimental spinal cord injury in rats. Neurochem Res 30:403–410. doi:10.1007/s11064-005-2615-2 PubMedCrossRef

21.

Miorelli ST, Rosa RM, Moura DJ, Rocha JC, Lobo LA, Henriques JA, Saffi J (2008) Antioxidant and anti-mutagenic effects of ebselen in yeast and in cultured mammalian V79 cells. Mutagenesis 23:93–99. doi:10.1093/mutage/gem048 PubMedCrossRef

22.

Hoshida S, Kuzuya T, Nishida M, Yamashita N, Hori M, Kamada T, Tada M (1994) Ebselen protects against ischemia-reperfusion injury in a canine model of myocardial infarction. Am J Physiol 267:H2342–H2347PubMed

23.

Maulik N, Yoshida T (2000) Oxidative stress developed during open heart surgery induces apoptosis: reduction of apoptotic cell death by ebselen, a glutathione peroxidase mimic. J Cardiovasc Pharmacol 36:601–608. doi:10.1097/00005344-200011000-00009 PubMedCrossRef

24.

Baljinnyam E, Hasebe N, Morihira M, Sumitomo K, Matsusaka T, Fujino T, Fukuzawa J, Ushikubi F, Kikuchi K (2006) Oral pretreatment with ebselen enhances heat shock protein 72 expression and reduces myocardial infarct size. Hypertens Res 29:905–913. doi:10.1291/hypres.29.905 PubMedCrossRef

25.

Ozaki M, Nakamura M, Teraoka S, Ota K (1997) Ebselen, a novel anti-oxidant compound, protects the rat liver from ischemia-reperfusion injury. Transpl Int 10:96–102PubMedCrossRef

26.

Noiri E, Nakao A, Uchida K, Tsukahara H, Ohno M, Fujita T, Brodsky S, Goligorsky MS (2001) Oxidative and nitrosative stress in acute renal ischemia. Am J Physiol Renal Physiol 281:F948–F957PubMed

27.

Dhanarajan R, Abraham P, Isaac B (2006) Protective effect of ebselen, a selenoorganic drug, against gentamicin-induced renal damage in rats. Basic Clin Pharmacol Toxicol 99:267–272. doi:10.1111/j.1742-7843.2006.pto_474.x PubMedCrossRef

28.

Yamasoba T, Pourbakht A, Sakamoto T, Suzuki M (2005) Ebselen prevents noise-induced excitotoxicity and temporary threshold shift. Neurosci Lett 380:234–238. doi:10.1016/j.neulet.2005.01.047 PubMedCrossRef

29.

Kil J, Pierce C, Tran H, Gu R, Lynch ED (2007) Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hear Res 226:44–51. doi:10.1016/j.heares.2006.08.006 PubMedCrossRef

30.

Cotgreave IA, Johansson U, Westergren G, Moldeus PW, Brattsand R (1988) The anti-inflammatory activity of Ebselen but not thiols in experimental alveolitis and bronchiolitis. Agents Actions 24:313–319. doi:10.1007/BF02028288 PubMedCrossRef

31.

Belvisi MG, Haddad EB, Battram C, Birrell M, Foster M, Webber S (2000) Anti-inflammatory properties of ebselen in a model of sephadex-induced lung inflammation. Eur Respir J 15:579–581. doi:10.1034/j.1399-3003.2000.15.25.x PubMedCrossRef

32.

Haddad el-B, McCluskie K, Birrell MA, Dabrowski D, Pecoraro M, Underwood S, Chen B, De Sanctis GT, Webber SE, Foster ML, Belvisi MG (2002) Differential effects of ebselen on neutrophil recruitment, chemokine, and inflammatory mediator expression in a rat model of lipopolysaccharide-induced pulmonary inflammation. J Immunol 169:974–982

33.

Bouhafs RK, Jarstrand C (2002) Effects of antioxidants on surfactant peroxidation by stimulated human polymorphonuclear leukocytes. Free Radic Res 36:727–734. doi:10.1080/10715760290032593 PubMedCrossRef

34.

Ogawa A, Yoshimoto T, Kikuchi H, Sano K, Saito I, Yamaguchi T, Yasuhara H (1999) Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial. Cerebrovasc Dis 9:112–118. doi:10.1159/000015908 PubMedCrossRef

35.

de Perrot M, Liu M, Waddell TK, Keshavjee S (2003) Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 167:490–511. doi:10.1164/rccm.200207-670SO PubMedCrossRef

36.

Stammberger U, Hamacher J, Hillinger S, Schmid RA (2000) sCR1sLeX ameliorates ischemia/reperfusion injury in experimental lung transplantation. J Thorac Cardiovasc Surg 120:1078–1084. doi:10.1067/mtc.2000.111175 PubMedCrossRef

37.

Sekido N, Mukaida N, Harada A, Nakanishi I, Watanabe Y, Matsushima K (1993) Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 365:654–657. doi:10.1038/365654a0 PubMedCrossRef

38.

DeMeester SR, Rolfe MW, Kunkel SL, Swiderski DL, Lincoln PM, Deeb GM, Strieter RM (1993) The bimodal expression of tumor necrosis factor-alpha in association with rat lung reimplantation and allograft rejection. J Immunol 150:2494–2505PubMed

39.

Jassem W, Roake J (1998) The molecular and cellular basis of reperfusion injury following organ transplantation. Transplant Rev 12:14–33. doi:10.1016/S0955-470X(98)80037-2 CrossRef

40.

Gater PR, Wasserman MA, Paciorek PM, Renzetti LM (1996) Inhibition of Sephadex-induced lung injury in the rat by Ro 45-2081, a tumor necrosis factor receptor fusion protein. Am J Respir Cell Mol Biol 14:454–460PubMed

41.

Renzetti LM, Paciorek PM, Tannu SA, Rinaldi NC, Tocker JE, Wasserman MA, Gater PR (1996) Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways. J Pharmacol Exp Ther 278:847–853PubMed

42.

Ochs M (2006) Stereological analysis of acute lung injury. Eur Respir Rev 15:115–121. doi:10.1183/09059180.00010102 CrossRef

43.

Waypa GB, Schandel NS, Schumacker PT (2001) Model for hypoxic pulmonary vasoconstriction involving mitochondrial oxygen sensing. Circ Res 88:1259–1266. doi:10.1161/hh1201.091960 PubMedCrossRef

44.

Stammberger U, Carboni GL, Hillinger S, Schneiter D, Weder W, Schmid RA (1999) Combined treatment with endothelin- and PAF-antagonists reduces posttransplant lung ischemia/reperfusion injury. J Heart Lung Transplant 18:862–868. doi:10.1016/S1053-2498(99)00039-X PubMedCrossRef

Title: Ebselen Improves Ischemia-Reperfusion Injury After Rat Lung Transplantation
Authors: Jürg Hamacher
Uz Stammberger
Elvira Weber
Rudolf Lucas
Albrecht Wendel
Publication date: 01-04-2009
Publisher: Springer-Verlag
Published in: Lung / Issue 2/2009
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-009-9134-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Lung Images: Chondrosarcoma on the Chest Wall

HLA Antigens and Nontuberculous Mycobacterial Lung Disease in Korean Patients

Association Between p53 codon 72 Genetic Polymorphism and Tobacco Use and Lung Cancer Risk

The Association Between Depressive Symptoms and Acute Exacerbations of COPD

Near-Drowning: Clinical Course of Lung Injury in Adults

Estrogen Replacement Therapy Prevents Airway Dysfunction in a Murine Model of Allergen-Induced Asthma

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials